Pay in 4 interest-free payments of $7.00 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Tirzepatide Dual GLP-1 / GIP Receptor Agonist Tirzepatide (LY3298176) is a first-in-class dual GIP/GLP-1 receptor agonist that has produced some of the most remarkable outcomes in metabolic research history
About TRIUMPH-4 and the TRIUMPH clinical trial program TRIUMPH-4 (NCT05869903) is a Phase 3, 68-week, randomized, double-blind, placebo-controlled study comparing the efficacy and safety of retatrutide with placebo in adults with obesity or overweight and knee osteoarthritis
Importantly, these results were replicated in the study population with 598,803 patients with type 2 diabetes
Cytotoxicity assay The cytotoxicity of WL-1 was tested on U251 and Vero cells
US$ 20.50
US$ 29.15
US$ 22.95
US$ 20.68
US$ 22.08
US$ 28.64
US$ 28.18
US$ 24.30
